United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
|
26.07.2024 22:00:00
|
Zm.
+1,8500
|
Wolumen |
Bid01:16:20 |
Ask01:16:20 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
|
338,2200USD
|
+0,55%
|
290 258
Obrót: 51,6 mln |
329,5100Wolumen Bid: 100 |
344,0000Wolumen Ask: 200 |
15 mldUSD |
- |
16,08 |
Opis działalności
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.
Zarząd & Rada nadzorcza
| CEO |
| Dr. Martine A. Rothblatt |
| Zarząd |
| James C. Edgemond, Michael Benkowitz, Paul A. Mahon |
| Rada nadzorcza |
| Dr. Martine A. Rothblatt, Christopher Causey, Christopher Patusky, Dr. Judy D. Olian, Linda Maxwell, M.D., Louis Sullivan, Nilda Mesa, Prof. Raymond Dwek, Ray Kurzweil, Richard Giltner, Tommy G. Thompson, Jan Malcolm |
Dane firmy
| Nazwa: |
United Therapeutics Corporation |
| Adres: |
1000 Spring Street,Silver Spring, Maryland 20910, USA |
| Telefon: |
+1-301-608-9292 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.unither.com/index |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
17.06.1999 |
Relacje inwestorskie
| Nazwa: |
- |
| Telefon: |
+1-301-608-9292 |
| Fax: |
- |
| E-mail: |
-
|
Główni akcjonariusze
| Freefloat |
|
61,80% |
| BlackRock, Inc |
|
9,60% |
| The Vanguard Group |
|
8,90% |
| Renaissance Technologies LLC |
|
8,10% |
| Avoro Capital Advisors LLC |
|
6,40% |
| FMR, LLC |
|
5,20% |
